International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn:
“2026 TTLC Symposia Event
Data and Decisions in Advanced NSCLC
The treatment landscape for advanced NSCLC is evolving rapidly, with new EGFR-targeted and ICI-based strategies reshaping first-line standards of care.
Join expert faculty at the 2026 TTLC Symposia for an engaging, discussion-driven session focused on navigating real-world complexity in advanced lung cancer. This program will tackle critical clinical dilemmas and deliver practical strategies to help personalize therapy and optimize patient outcomes.
Key reasons to attend:
- Stay current on breakthrough EGFR-targeted and ICI-based approaches
- Tackle real-world challenges in treatment decision-making
- Walk away with practical tools to elevate patient care.”
Other articles about IASLC.